Literature DB >> 29875316

CD83 expression is essential for Treg cell differentiation and stability.

Marina Doebbeler1, Christina Koenig1, Lena Krzyzak1, Christine Seitz1, Andreas Wild1, Thomas Ulas2, Kevin Baßler2, Dmitry Kopelyanskiy2, Alina Butterhof1, Christine Kuhnt1, Simon Kreiser1, Lena Stich1, Elisabeth Zinser1, Ilka Knippertz1, Stefan Wirtz3, Christin Riegel4, Petra Hoffmann4, Matthias Edinger4, Lars Nitschke5, Thomas Winkler5, Joachim L Schultze2, Alexander Steinkasserer1, Matthias Lechmann1.   

Abstract

Foxp3-positive regulatory T cells (Tregs) are crucial for the maintenance of immune homeostasis and keep immune responses in check. Upon activation, Tregs are transferred into an effector state expressing transcripts essential for their suppressive activity, migration, and survival. However, it is not completely understood how different intrinsic and environmental factors control differentiation. Here, we present for the first time to our knowledge data suggesting that Treg-intrinsic expression of CD83 is essential for Treg differentiation upon activation. Interestingly, mice with Treg-intrinsic CD83 deficiency are characterized by a proinflammatory phenotype. Furthermore, the loss of CD83 expression by Tregs leads to the downregulation of Treg-specific differentiation markers and the induction of an inflammatory profile. In addition, Treg-specific conditional knockout mice showed aggravated autoimmunity and an impaired resolution of inflammation. Altogether, our results show that CD83 expression in Tregs is an essential factor for the development and function of effector Tregs upon activation. Since Tregs play a crucial role in the maintenance of immune tolerance and thus prevention of autoimmune disorders, our findings are also clinically relevant.

Entities:  

Keywords:  Autoimmune diseases; Autoimmunity; Immunology; T cell development; Tolerance

Mesh:

Substances:

Year:  2018        PMID: 29875316      PMCID: PMC6124443          DOI: 10.1172/jci.insight.99712

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  55 in total

1.  Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity.

Authors:  Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Med       Date:  2002-07-29       Impact factor: 53.440

2.  Prevention of chronic renal allograft rejection by soluble CD83.

Authors:  Zhu Lan; Dameng Lian; Weihua Liu; Jacqueline Arp; Brayden Charlton; Wei Ge; Stephen Brand; Don Healey; Mark DeBenedette; Charles Nicolette; Bertha Garcia; Hao Wang
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

Review 3.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

4.  CD83 Modulates B Cell Activation and Germinal Center Responses.

Authors:  Lena Krzyzak; Christine Seitz; Anne Urbat; Stefan Hutzler; Christian Ostalecki; Joachim Gläsner; Andreas Hiergeist; André Gessner; Thomas H Winkler; Alexander Steinkasserer; Lars Nitschke
Journal:  J Immunol       Date:  2016-03-16       Impact factor: 5.422

5.  In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy.

Authors:  C Becker; M C Fantini; S Wirtz; A Nikolaev; R Kiesslich; H A Lehr; P R Galle; M F Neurath
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival.

Authors:  Felix Bock; Susanne Rössner; Jasmine Onderka; Matthias Lechmann; Maria Teresa Pallotta; Francesca Fallarino; Louis Boon; Charles Nicolette; Mark A DeBenedette; Irina Y Tcherepanova; Ursula Grohmann; Alexander Steinkasserer; Claus Cursiefen; Elisabeth Zinser
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

7.  Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.

Authors:  Zizhen Kang; Cengiz Zubeyir Altuntas; Muhammet Fatih Gulen; Caini Liu; Natalia Giltiay; Hongwei Qin; Liping Liu; Wen Qian; Richard M Ransohoff; Cornelia Bergmann; Stephen Stohlman; Vincent K Tuohy; Xiaoxia Li
Journal:  Immunity       Date:  2010-03-18       Impact factor: 31.745

8.  A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts.

Authors:  Jun-Fa Xu; Bao-Jun Huang; Hui Yin; Ping Xiong; Wei Feng; Yong Xu; Min Fang; Fang Zheng; Cong-Yi Wang; Fei-Li Gong
Journal:  Transpl Int       Date:  2007-03       Impact factor: 3.782

9.  The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.

Authors:  Matthias Lechmann; Naomi Shuman; Andrew Wakeham; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  22 in total

1.  Putative loss of CD83 immunosuppressive activity in long-standing complication-free juvenile diabetic patients during disease progression.

Authors:  Ulana Juhas; Monika Ryba-Stanisławowska; Urszula Ławrynowicz; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Mucosal viral infection induces a regulatory T cell activation phenotype distinct from tissue residency in mouse and human tissues.

Authors:  Brianna Traxinger; Sarah C Vick; Amanda Woodward-Davis; Valentin Voillet; Jami R Erickson; Julie Czartoski; Candice Teague; Martin Prlic; Jennifer M Lund
Journal:  Mucosal Immunol       Date:  2022-07-11       Impact factor: 8.701

3.  Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Authors:  James C Lee; Sadaf Mehdizadeh; Jennifer Smith; Arabella Young; Ilgiz A Mufazalov; Cody T Mowery; Adil Daud; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2020-10-02

4.  CD83 orchestrates immunity toward self and non-self in dendritic cells.

Authors:  Andreas B Wild; Lena Krzyzak; Katrin Peckert; Lena Stich; Christine Kuhnt; Alina Butterhof; Christine Seitz; Jochen Mattner; Niklas Grüner; Maximilian Gänsbauer; Martin Purtak; Didier Soulat; Thomas H Winkler; Lars Nitschke; Elisabeth Zinser; Alexander Steinkasserer
Journal:  JCI Insight       Date:  2019-10-17

5.  Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease.

Authors:  Katherine E Olson; Krista L Namminga; Yaman Lu; Mackenzie J Thurston; Aaron D Schwab; Seymour de Picciotto; Sze-Wah Tse; William Walker; Jared Iacovelli; Clayton Small; Brian T Wipke; R Lee Mosley; Eric Huang; Howard E Gendelman
Journal:  Biomaterials       Date:  2021-03-31       Impact factor: 12.479

6.  Epithelial cell-derived CD83 restores immune tolerance in the airway mucosa by inducing regulatory T-cell differentiation.

Authors:  Li-Hua Mo; Xiang-Qian Luo; Gui Yang; Jiang-Qi Liu; Li-Teng Yang; Zhi-Qiang Liu; Shuai Wang; Da-Bo Liu; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

7.  Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.

Authors:  Carol M Amato; Jennifer D Hintzsche; Keith Wells; Allison Applegate; Nicholas T Gorden; Victoria M Vorwald; Richard P Tobin; Kelsey Nassar; Yiqun G Shellman; Jihye Kim; Theresa M Medina; Matthew Rioth; Karl D Lewis; Martin D McCarter; Rene Gonzalez; Aik-Choon Tan; William A Robinson
Journal:  Cancers (Basel)       Date:  2020-07-17       Impact factor: 6.639

8.  Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.

Authors:  Dmytro Royzman; Darja Andreev; Lena Stich; Manfred Rauh; Tobias Bäuerle; Stephan Ellmann; Louis Boon; Markus Kindermann; Katrin Peckert; Aline Bozec; Georg Schett; Alexander Steinkasserer; Elisabeth Zinser
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

Review 9.  CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Authors:  Ziduo Li; Xinsheng Ju; Pablo A Silveira; Edward Abadir; Wei-Hsun Hsu; Derek N J Hart; Georgina J Clark
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

10.  Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Authors:  Bishwas Shrestha; Kelly Walton; Jordan Reff; Elizabeth M Sagatys; Nhan Tu; Justin Boucher; Gongbo Li; Tayyebb Ghafoor; Martin Felices; Jeffrey S Miller; Joseph Pidala; Bruce R Blazar; Claudio Anasetti; Brian C Betts; Marco L Davila
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.